Global Nasal Splints Market

Central Nervous System Drugs Market Definition

The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The CNS drugs include anesthetics, anticonvulsants, antiemetics, antiparkinsonian agents, CNS stimulants, analgesics, and sedatives. Neurological diseases such as Epilepsy, Parkinson and psychological indications such as depression, and dementia are generally treated through these CNS drugs. Nervous system disorders are defined as disorders that affect the brain as well as the nerves found throughout the human body and the spinal cord. Structural, biochemical or electrical abnormalities in the brain, spinal cord or other nerves can result in a range of symptoms. Some of the common clinical indications of such disorders include paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain and altered levels of consciousness. These also include mental health conditions such as depression and post-traumatic stress disorder (PTSD). The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities.

The ENT surgical devices and equipment market consists of sales of ENT (ear-nose-throat) surgical devices. ENT surgical devices include balloon sinus dilation devices, powered surgical instruments, ENT supplies, radiofrequency devices, ear tubes, and handheld instruments are used to perform surgical procedures such as tonsillectomy, tracheostomy, implantations, septorhinoplasty, turbinate reduction, mastoidectomy, stapedectomy, and reconstruction surgeries. The main products in ENT surgical devices and equipment are hand instruments, ENT surgical lasers, powered ENT surgical systems, radiofrequency electrosurgical devices, ENT surgery workstations, ENT surgical navigation system, ENT visualization system, and surgical microscopes. These devices and equipment are hand-held devices, portable devices, and fixed devices. The various end-users are hospitals, ambulatory surgical centers, and ENT clinics. The global ENT surgical devices and equipment market size is expected to grow from $4.69 billion in 2021 to $5.25 billion in 2022 at a compound annual growth rate (CAGR) of 11.9%. The global ENT surgical devices market size is expected to grow to $7.95 billion in 2026 at a CAGR of 10.9%. Increasing demand and adoption of minimally invasive ENT surgeries will drive the ENT surgical devices and equipment market in the future. For example, minimally invasive ENT surgeries offer patients many benefits such as smaller incisions, faster recovery times, reduced pain, and scarring. In the majority of the cases, physicians enjoy a higher accuracy rate compared to traditional open surgery. These supreme benefits of minimally invasive ENT surgeries will drive the market. Lack of proper reimbursement policies for ENT surgical procedures, especially in developing and developed countries, is one of the major factors that could hinder the growth of the ENT surgical devices and equipment market. ENT surgical procedures are complex, involve greater devices, and thus are relatively expensive. The lack of proper reimbursement policies may inhibit the growth of the ENT surgical devices and equipment market. ENT procedures involving minimally invasive ENT tools are an alternative to major surgeries. It involves less tissue damage, reduced scarring, and faster recovery thereby leading to greater adoption and would see an increase in the market potential. Robot-assisted minimally invasive ENT procedures have transformed the treatment landscape of cancer associated with the ear, nose, and throat. For treating benign and malignant conditions of the oropharynx and larynx, Transoral robotic surgery (TORS) is now being widely adopted. The ENT surgical devices and equipment industry has lately witnessed a rise in the number of FDA clearances which would positively impact the market growth. A pre-market approval by FDA through FDA 510(K) is required for all the medical devices including ENT surgical devices. As announced by the FDA, the FDA 510(K) is expected to see several updates to regulate safety, technology, and capabilities in the medical devices space. The European Union’s Medical Device Regulation (MDR) presented a few changes that would come into force by 2020. The changes made to the regulation were in terms of recertification of legacy devices, as well as changes in the definition of regulated devices, safety measures, and risk management. In 2020, Intersect ENT, a USA-based ear, nose, and throat condition treatment developer, announced to acquire Fiagon for USD 71.1 million. The acquisition was aimed to help Intersect ENT to expand its product portfolio and to extend its geographical reach. Fiagon develops surgical navigation systems that support both routine and complex ENT procedures and is based in Germany. Major players in the ENT surgical devices and equipment market are Carl Zeiss Meditec AG, Stryker, Shanghai Fosun Pharmaceuticals Ltd, KLS Martin LP, Acclarent Inc, Medtronic, Smith & Nephew, Boston Scientific, Olympus, and ClaroNav. Asia Pacific was the largest region in the ENT surgical devices and equipment market in 2021. North America was the second-largest region in the global ENT surgical equipment market. The regions covered in the global ENT surgical devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in ENT surgical devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global ENT surgical devices and equipment market is segmented - 1) By Modality: Hand-Held Devices, Portable Devices, Fixed Devices 2) By End-User: Hospitals, Ambulatory Surgical Centers, ENT Clinics 3) By Product: Hand Instrument, ENT Surgical Lasers, Powered ENT Surgical Systems, Radiofrequency Electrosurgical Devices, ENT Surgery Workstations, ENT Surgical Navigation System, ENT Visualization System, Surgical Microscopes

The bronchoscopy market consists of sales of bronchoscopes and bronchoscopy services. Bronchoscopy is a technique for visualizing inside airways or lungs for therapeutic and diagnostic purposes. In bronchoscopy, an instrument is inserted into the airways through the nose, mouth, or sometimes through a tracheostomy through which the practitioner can examine the patient's airways for any infections. The bronchoscopy market covered in this report is segmented by product into bronchoscopes, imaging systems, cytology brushes, and others. The bronchoscopes are the type of endoscopes that are used to examine a patient's larynx, throat, trachea, and lower airways. The bronchoscopy working channel diameter consists of 2.8 mm, 2.2 mm, 3.0 mm, and others that are used for adult patients and pediatric/neonate patients. The various applications of bronchoscopy are bronchial treatment and bronchial diagnosis. The global bronchoscopy market size is expected to grow from $2.54 billion in 2021 to $2.81 billion in 2022 at a compound annual growth rate (CAGR) of 10.9%. The global bronchoscopy market is expected to grow to $3.52 billion in 2026 at a CAGR of 5.8%. The growing prevalence of respiratory diseases contributed to the growth of the bronchoscopy market. According to the American Cancer Society 2020, in the United States, about 228,820 new cases of lung cancer and about 135,720 deaths from lung cancer. Therefore, the increasing prevalence of respiratory diseases around the world, especially the COVID-19 outbreak in 2020, will drive the bronchoscopy market. The risk of contamination of devices has been a major challenge in the bronchoscopy market. According to the center for disease control and prevention, in the USA, there are around 6.8 lakhs of hospital-acquired infection cases and 72,000 hospital-acquired infection patients die. Multiple factors including contamination of devices are the reasons for hospital-acquired infection. This can be due to improper cleaning of devices or improper maintenance of the storage rooms and other factors. The risk of contamination of devices has a negative impact on the growth of the bronchoscopy market. The single-use flexible bronchoscopes are increasingly being used to prevent the risk of contamination of devices. The single-use flexible bronchoscopes are longer and thinner tubes that allow seeing the deep areas of the bronchus and are much easier to change and have a clear image of position inside the lung bronchus. The single-use flexible bronchoscopes improve safety and productivity. In April 2019, Johnson & Johnson acquired Auris Health Inc for a deal amount of $3.4 billion. Auris Health's robotic platform technology is used for diagnostic and therapeutic procedures in the lungs. Johnson & Johnson is focused on building a connected, data-driven digital ecosystem that pairs one of the surgical solutions with advanced technologies to improve the patient’s experience. Major players in the bronchoscopy market are Olympus Corporation, Karl Storz, Fujifilm Holdings Corporation, Ambu A/S, Boston Scientific, Hoya Corporation, Richard Wolf GmbH, Cook Medical, Lymol Medical, and F. Hoffmann-La Roche Ltd. The regions covered in the global bronchoscopy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bronchoscopy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global bronchoscopy market is segmented - 1) By Product: Bronchoscopes, Imaging Systems, Cytology Brushes, Others 2) By Application: Bronchial Treatment, Bronchial Diagnosis 3) By Working Channel Diameter: 2.8 mm, 2.2 mm, 3.0 mm, Others 4) By Patient Age: Adult Patients, Pediatric/Neonate Patients

The laryngoscope market consists of sales of laryngoscopes and related services by entities (organizations, sole traders, and partnerships) that manufacture laryngoscopes. A laryngoscope is a medical device used to view and examine the larynx and vocal cords in the throat. This device is also used during tracheal intubation in patients requiring ventilator support. Only goods and services traded between entities or sold to end consumers are included. The main types of the laryngoscope market are indirect laryngoscope and direct laryngoscope. The direct laryngoscope is the procedure that allows visualization of the larynx during general anesthesia, surgical procedures. The various product involved is video laryngoscopes, standard laryngoscopes, and fiber-optic laryngoscopes. The various end-users are hospitals, clinics, and medical examination centers. The global laryngoscope market size is expected to grow from $0.23 billion in 2021 to $0.25 billion in 2022 at a compound annual growth rate (CAGR) of 10.8%. The global laryngoscope market is then expected to grow to $0.38 billion in 2026 at a CAGR of 10.6%. The growing prevalence of laryngeal cancers, infections, and chronic respiratory diseases are one of the key reasons expected to boost laryngoscope market growth. Laryngeal cancer is head and neck cancer that occurs when abnormal (malignant) cells form in the larynx. In 2019, there were 88,878 male deaths and 13,762 female deaths worldwide from larynx cancer. Moreover, in 2020, in the United States, there were 12,370 new cases and 3,750 deaths from laryngeal cancer. Therefore, the increasing prevalence of laryngeal cancer increased the demand for laryngoscopes and thereby contributed to market growth. Soft tissue injury caused by a laryngoscope is a restraining factor for the laryngoscope market. The most common complication is an injury to the soft palate, although injuries also occur to the teeth, larynx, tongue, and retromolar trigone. The oropharynx is specifically at risk of injury because the video laryngoscope causes the tonsillar pillars to elevate and stretch anteriorly, making them more prone to injury as the tube is being advanced. The soft tissue damage in traditional laryngoscopy is caused mainly by insertion of the laryngoscope, but soft tissue injury with the video laryngoscope is caused by insertion of the endotracheal tube (ETT) itself, as it is often designed blindly into and through the oral cavity and pharynx until it is finally in view at the video laryngoscope monitor. The complications caused demand for a better device, restraining the laryngoscope market. Robot-assisted laryngoscopy is one of the key trends shaping the laryngoscope market. Growing complications or risks associated with advanced and experimental procedures contribute to increased demand for robot-assisted laryngoscopy. The characteristics of robot-assisted devices such as reliability will increase precision levels and have near-absolute geometric accuracy, which helps to reduce the workload of the specialists and improve patient care. Implementing robotic systems leads to faster skill development than manual procedures, and also improves performance and safety. Johns Hopkins University developed a robotic tool to improve surgeons' access to the larynx (voice box). The experts are designing a robotic laryngoscope that can be used with one hand like a joystick. In January 2019, Dilon Technologies, a global leader in designing, manufacturing, and commercializing innovative medical imaging solutions, acquired the CoPilot VL video laryngoscope for an undisclosed amount. This acquisition will help Dilon Technologies expand its footprint in the anesthesia and airway field. CoPilot VL joins Dilon's growing range of imaging and intraoperative devices, including its Molecular Breast Imaging Program for breast cancer diagnosis and the Dilon Navigator Gamma Cancer Surgery Probe. Major players in the laryngoscope market are Ambu, Hill-Rom Holdings, Inc, KARL STORZ, Medtronic, Olympus, HOYA, Roper Technologies, Inc. (Verathon, Inc.), Richard Wolf GmbH, Schoelly Fiberoptic GmbH, and Welch Allyn Inc. Asia Pacific was the largest region in the laryngoscope market in 2021. North America was the second largest region in the global laryngoscope market. Eastern Europe was the smallest region in the laryngoscopes market. The regions covered in the global laryngoscope market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the laryngoscope market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global laryngoscope market is segmented - 1) By Type: Indirect Laryngoscope, Direct Laryngoscope 2) By Product: Video Laryngoscopes, Standard Laryngoscopes, Fiber-Optic Laryngoscopes 3) By End-User: Hospitals, Clinics, Medical Examination Center

The cold and cough preparations market consists of sales of drugs for cold and cough. The drugs for the treatment of cold and cough acts on the receptors to which the virus causing the infection gets attached to, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. In this market, sales of antihistamines, antibiotics, decongestants, expectorants and bronchodilators are also included. The main types of drugs in cold and cough preparations are antihistamines, expectorants, bronchodilators, decongestants, antibiotics, others. Antihistamines are drugs or other compounds that block the physiological effects of histamine, and are used to treat allergies in particular. The different types include bronchodialators, anticholinergic, pulmonary antihypertensives. The several dosage types include oral syrups, tablets or pills, nasal drops, lozenges, others and distributed through various channels such as hospital pharmacies, retail pharmacies and drug stores. The global cough and cold preparations market size is expected to grow from $61.84 billion in 2021 to $66.61 billion in 2022 at a compound annual growth rate (CAGR) of 7.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global cough and cold preparation market is expected to reach $84.89 billion in 2026 at a CAGR of 6.2%. Threat from substitute products such as generic and counterfeit drugs, is significantly restraining the global cold and cough preparations market. Pharmaceutical companies invest a large sum of money in drug development process. Once a drug candidate is developed and approved by the regulatory authorities, companies patent their inventions to protect their intellectual property. During the patency period, the company holding the patent holds exclusivity for manufacturing and distribution. Post expiration of patency, generic versions of the drugs are manufactured by other companies. The prices of the generics are very low in comparison to the original brand of the drug. According to an article of Alpha Invesco, a new FDA-approved blockbuster drug that netted $100 million a year in profit during its patent protection duration could become one that earns only $1 million a year in profit overnight after losing its patent. Additionally, there is a major international problem with counterfeit drugs. The best of these counterfeits duplicates a real drug’s formula and sells it at a lower price, which hurts pharmaceutical companies' profits. Moreover, the counterfeits made with low-grade materials can destroy the reputations of the legitimate products, thus affecting the growth of the market. Advancements in technologies are driving the global pharmaceutical sector including cold and cough preparations. According to global life sciences report by Deloitte, adoption of AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine are the major technologies driving the life sciences sector. AI technology is being used in diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is allowing new business models to emerge and enhancing customer experiences. Pharmaceutical companies are also increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators which are objectively measured and evaluated for biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. The cold and cough preparations market is regulated by authorities such as the Food and Drug Administration in the US. For instance, the Food and Drug Administration (FDA) restricted the use of codeine in children. Codeine is approved to treat pain and cough but this medicine carries serious risks, including slowed or difficult breathing and can be potentially fatal. This risk is greater in children younger than 12 years but the use of codeine should also be limited in some older children. Single-ingredient codeine is FDA-approved only for use in adults. FDA is also recommending against the use of codeine in breastfeeding mothers due to possible harm to their infants. Major players in the cold and cough preparation market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline, Himalaya Global Holdings, Hyland's, Johnson & Johnson, Novartis and Perrigo Company. North America was the largest region in the cold and cough preparation market in 2021. The Middle East is expected to be the fastest growing region in the global cold and cough medicine market during the forecast period. The regions covered in the global cough and cold market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cold and cough preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cough and cold preparations market is segmented - 1) By Type: Bronchodialators, Anticholinergic, Pulmonary Antihypertensives 2) By Drug Type: Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Others 3) By Dosage Type: Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Others 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores

The drug delivery devices market consists of the sales of medical devices and equipment that are used for delivering specific drugs to a specific part of the body to cure chronic diseases such as cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases. The main route of administration of drug delivery devices are oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care setting is hospitals, diagnostic centers, ambulatory surgery centers/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The global drug delivery devices market size is expected to grow from $79.68 billion in 2021 to $84.1 billion in 2022 at a compound annual growth rate (CAGR) of 5.5%. The global drug delivery device market size is then expected to grow to $100.1 billion in 2026 at a CAGR of 4.5%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the World Health Organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors – the effect desired, the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in pharmaceutical industries. Research and development (R&D) in drug delivery are increasing throughout the world due to increasing prevalence of these diseases. Most of the pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcome for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. Drugs used for COVID-19 treatment are both oral and injectable, however, a marginal increase is expected for pulmonary or respiratory-based drug delivery devices. The regulatory changes related to medical devices is expected to restraint the growth of drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, penalties at a global level. The new MDSAP will come into effect from 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include, 3M, Vetter Pharma International GmbH, nano Biosciences LLC, Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as to expand their footprint across different geographies. For example, in December 2019, Leo Pharma, a Danish pharmaceutical company, has collaborated with Portal Instruments to build Portal's advanced needle-free drug delivery system for use in conjunction with LEO Pharma's research and approved drug portfolio. This simplifies administration and removes the need for sharp containers at home, and also decreases the time required for self-injections. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd, 3M Company, Pfizer Inc, Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc, Bayer AG, and GlaxoSmithKline plc. North America was the largest region in the drug delivery devices market in 2021. Asia Pacific was the second-largest region in the global drug delivery devices market. The regions covered in the global drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global drug delivery devices market is segmented - 1) By Route of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Others 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Others

The ENT devices market consists of sales of ENT devices and related services by entities (organizations, sole traders, and partnerships) that produce ENT devices used in the diagnosis and treatment of ear, nose, and throat diseases. The main types of ENT devices are hearing aid devices and equipment, hearing diagnostic devices and equipment, ENT surgical devices and equipment, hearing implants, voice prosthesis devices and equipment, and nasal splints. A hearing aid device is an electronic device that is worn in or behind the ear. It makes sounds louder so that a person with hearing loss can listen, communicate, and participate fully in daily activities. The type of expenditure is public and private. The products used are instruments/equipment, and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The global ENT devices market size is expected to grow from $27.1 billion in 2021 to $30.21 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The global ENT device market size is then expected to grow to $44.73 billion in 2026 at a CAGR of 10.3%. Many governments across the world have introduced new healthcare acts and continuously increased healthcare spending. Healthcare coverage and expenditure also increased significantly. In 2021, the Indian government launched Ayushman Bharat PradhanMantri Jan ArogyaYojana (AB-PMJAY) is providing health assurance cover of up to ?5 Lakh per year per family for secondary and tertiary healthcare hospitalizations. The healthcare services market in the UK increased by $300.8 billion in 2019. Favorable government decisions and increased healthcare spending increased the demand for healthcare services and this drove the demand for ENT devices during this period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates are expected to rise to 3.5% by 2021. These factors are expected to have a negative impact on the market as borrowing money becomes expensive, thereby affecting the market growth. ENT device manufacturers are investing in technologies to develop user-friendly and non-invasive equipment. They are continuously investing funds and resources into R&D to increase the scope of their devices. For instance, Intersect ENT developed Propel Mometasone Furoate Implant (PMFI) to treat chronic sinusitis. It is a bio-absorbable steroid that is placed directly into the sinus mucosa. It controls the release of drugs and dissolves over time. In another breakthrough in sinusitis treatment, SinuSys Corporation received FDA approval for its Vent-Os Sinus Dilation device. It is a small, low-pressure insert that is designed to gently open the sinus ostia and use the body’s natural mucosal fluids to expand the device. Major companies in the ENT devices market include Sonova Holdings AG, William Demant Holdings A/S, Medtronic Inc., GN Store Nord A/S, Cochlear Limited, Olympus Corporation, Stryker Corporation, Karl Storz SE & Co KG, Merck & Co, and Smith & Nephew plc. Asia Pacific was the largest region in the global ENT devices market in 2021. North America was the second largest region in the global ENT device market. Africa was the smallest region in the global ENT market. The regions covered in the global ENT devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ENT devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The global ENT devices market is segmented - 1) By Type: Hearing Aid Devices and Equipment, Hearing Diagnostic Devices and Equipment, ENT Surgical Devices and Equipment, Hearing Implants, Voice Prosthesis Devices and Equipment, Nasal Splints 2) By End-User: Hospitals and Clinics, Diagnostic Laboratories, Others 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The market for airway management devices consists of sales of airway management devices and related services. Airway management devices are used to prevent and relieve airway obstruction to ensure the proper exchange of air between the patient’s lungs and atmosphere. The main types of airway management devices are infraglottic airway management devices, supraglottic airway management devices, resuscitators, laryngoscopes, and other devices. The infraglottic airway management devices are used to prevent and relieve airway obstruction to ensure the proper exchange of air between the patient’s lungs and atmosphere. These are used for applications such as anesthesia, emergency medicine, others that are used by hospitals and homecare. The global airway management devices market size is expected to grow from $2.19 billion in 2021 to $2.36 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The global airway management device market size is expected to grow to $2.76 billion in 2026 at a CAGR of 4.0%. The increasing prevalence of respiratory diseases is expected to propel the demand for airway management devices market over the forecast period. Airway management devices are used for difficult emergency airway management during medical procedures. According to the publication of United for Lung Health in 2019, a forum of international respiratory societies, chronic obstructive pulmonary disease (COPD) is the third leading cause of death with an average of 384 million people suffering from COPD each year. Lung cancer was the deadliest cancer with 1.76 million deaths annually across the world. Moreover, 10 million people develop tuberculosis and 334 million people suffer from asthma every year. This scenario drives the growth of the airway management devices market. The complications and failures associated with airway management devices limit the growth of airway management devices. According to BioMed Research International Journal, the concerns or complications related to the supraglottic and other airway management devices include compression of vascular structures, regurgitation, aspiration of gastric contents, trauma, and nerve injury. Therefore, higher incidences of complications associated with the airway management devices question the use of devices in the first place and likely harm the market growth. The launch of innovative airway management devices is shaping the airway management devices market. For instance, in January 2019, Verathon, a medical device manufacturer specializing in airway management devices, announced the launch of GlideScope Core, the most flexible and comprehensive airway visualization system available for bronchoscopy, video laryngoscopy, and multimodal airway procedures. GlideScope Core was the first airway visualization system with live and simultaneous picture-in-picture imaging which offers healthcare professionals the power to see and do more. Similarly, in June 2020, Docsinnovent Ltd launched an advanced version of V-gel, which is a supraglottic airway device for cats and rabbits. Major players in the global airway management devices market are Medtronic, Smiths Medical (A Division of Smiths Group PLC), Teleflex, Ambu, Karl Storz, Flexicare, Intersurgical, Carefusion, Mercury Medical, and Well Lead Medical Co Ltd. The regions covered in the global airway management devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the global airway management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global airway management devices market is segmented - 1) By Type: Infraglottic Airway Management Devices, Supraglottic Airway Management Devices, Resuscitators, Laryngoscopes, Others 2) By End-Use: Hospital, Homecare 3) By Application: Anesthesia, Emergency Medicine, Others